Local serum levels of vascular endothelial growth factor in infantile hemangioma: Intriguing mechanism of endothelial growth

Przewratil, Przemysław; Sitkiewicz, Anna; Andrzejewska, Ewa

doi:10.1016/j.cyto.2009.11.012

Cited by 67 publications

(66 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The initial VEGF-C level was elevated compared with the few data available for healthy infants, but all of them referring to VEGF-A. [9][10][11][12][13] In 5 preterm infants with retinopathy of prematurity who were treated with the monoclonal VEGF antibody bevacizumab, a similar decrease in VEGF-A levels has been observed. 14 Recently, Ozeki et al 15 reported on propranolol therapy for pediatric lymphatic malformation.…”

Section: Discussionmentioning

confidence: 96%

Treatment of Congenital Generalized Lymphangiectasia With Propranolol in a Preterm Infant

Poralla¹,

Specht

Born

et al. 2014

Pediatrics

View full text Add to dashboard Cite

Generalized lymphangiectasia is a rare congenital disorder characterized by dilated lymphatic vessels with a fatal prognosis, especially in cases with thoracic involvement. We describe the use of propranolol in the therapy of generalized lymphangiectasia in a preterm infant with hydrops fetalis. Propranolol was well tolerated and effective within the first months. It remains to be shown whether propranolol is a treatment option for infants with generalized lymphangiectasia.

show abstract

Section: Discussionmentioning

confidence: 96%

Treatment of Congenital Generalized Lymphangiectasia With Propranolol in a Preterm Infant

Poralla¹,

Specht

Born

et al. 2014

Pediatrics

View full text Add to dashboard Cite

show abstract

“…A similar dependence was observed by other authors, although they found remarkably low levels of this factor in the material taken directly from the hemangioma, both in the proliferative phase and in the involution. 19,20 The proangiogenic properties of VEGF, as well as the effect of glucocorticoids on angiogenesis and vasculogenesis, have been reported in animal models. 21 After the implantation of stem cells producing vascular endothelial growth factor A (VEGF-A) in mice and simultaneous administration of dexamethasone, other researchers observed a decrease in VEGF value and symptoms of atrophic decompression.…”

Section: Resultsmentioning

confidence: 99%

Serum concentrations of VEGF and bFGF in the course of propranolol therapy of infantile hemangioma in children: Are we closer to understand the mechanism of action of propranolol on hemangiomas?

et al. 2018

View full text Add to dashboard Cite

Background. Propranolol has become the treatment of choice for infantile hemangiomas (IH). Neither the pathogenesis of IH nor the mechanism of action of propranolol on them are well understood. Possible explanations include the inhibition of angiogenesis by decreasing vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), induction of vascular endothelial cell apoptosis and vasoconstriction.

show abstract

“…in the involuting phase, VEGF expression rapidly decreases, and many angiogenesis inhibitors become prominent [21,27,28]. The functions of the different VEGF family members are determined by their receptor specificity.…”

Section: Hemangioma-derived Pericytementioning

confidence: 99%

Wnt3a Expression is Associated with MMP-9 Expression in Primary Tumor and Metastatic Site in Recurrent or Stage IV Colorectal Cancer

2014

Cancer Cell Signaling

View full text Add to dashboard Cite

Infantile hemangioma (IH), which is the most common tumor in infants, is a benign vascular neoplasm resulting from the abnormal proliferation of endothelial cells and pericytes. For nearly a century, researchers have noted that IH exhibits diverse and often dramatic clinical behaviors. On the one hand, most lesions pose no threat or potential for complication and resolve spontaneously without concern in most children with IH. On the other hand, approximately 10% of IHs are destructive, disfiguring and even vision-or life-threatening. Recent studies have provided some insight into the pathogenesis of these vascular tumors, leading to a better understanding of the biological features of IH and, in particular, indicating that during hemangioma neovascularization, two main pathogenic mechanisms prevail, angiogenesis and vasculogenesis. Both mechanisms have been linked to alterations in several important cellular signaling pathways. These pathways are of interest from a therapeutic perspective because targeting them may help to reverse, delay or prevent hemangioma neovascularization. In this review, we explore some of the major pathways implicated in IH, including the VEGF/VEGFR, Notch, β-adrenergic, Tie2/angiopoietins, PI3K/AKT/mTOR, HIF-α-mediated and PDGF/PDGF-R-β pathways. We focus on the role of these pathways in the pathogenesis of IH, how they are altered and the consequences of these abnormalities. In addition, we review the latest preclinical and clinical data on the rationally designed targeted agents that are now being directed against some of these pathways.

show abstract

Local serum levels of vascular endothelial growth factor in infantile hemangioma: Intriguing mechanism of endothelial growth

Cited by 67 publications

References 22 publications

Treatment of Congenital Generalized Lymphangiectasia With Propranolol in a Preterm Infant

Treatment of Congenital Generalized Lymphangiectasia With Propranolol in a Preterm Infant

Serum concentrations of VEGF and bFGF in the course of propranolol therapy of infantile hemangioma in children: Are we closer to understand the mechanism of action of propranolol on hemangiomas?

Wnt3a Expression is Associated with MMP-9 Expression in Primary Tumor and Metastatic Site in Recurrent or Stage IV Colorectal Cancer

Contact Info

Product

Resources

About